286 related articles for article (PubMed ID: 8555226)
1. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.
Newton DL; Xue Y; Olson KA; Fett JW; Rybak SM
Biochemistry; 1996 Jan; 35(2):545-53. PubMed ID: 8555226
[TBL] [Abstract][Full Text] [Related]
2. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
3. Cloning and cytotoxicity of a human pancreatic RNase immunofusion.
Zewe M; Rybak SM; Dübel S; Coy JF; Welschof M; Newton DL; Little M
Immunotechnology; 1997 Jun; 3(2):127-36. PubMed ID: 9237097
[TBL] [Abstract][Full Text] [Related]
4. Inclusion of a furin-sensitive spacer enhances the cytotoxicity of ribotoxin restrictocin containing recombinant single-chain immunotoxins.
Goyal A; Batra JK
Biochem J; 2000 Jan; 345 Pt 2(Pt 2):247-54. PubMed ID: 10620501
[TBL] [Abstract][Full Text] [Related]
5. Medical applications of single-chain antibodies.
Huston JS; McCartney J; Tai MS; Mottola-Hartshorn C; Jin D; Warren F; Keck P; Oppermann H
Int Rev Immunol; 1993; 10(2-3):195-217. PubMed ID: 8360586
[TBL] [Abstract][Full Text] [Related]
6. Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv.
Newton DL; Nicholls PJ; Rybak SM; Youle RJ
J Biol Chem; 1994 Oct; 269(43):26739-45. PubMed ID: 7929408
[TBL] [Abstract][Full Text] [Related]
7. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
8. Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation.
Siemers NO; Kerr DE; Yarnold S; Stebbins MR; Vrudhula VM; Hellström I; Hellström KE; Senter PD
Bioconjug Chem; 1997; 8(4):510-9. PubMed ID: 9258449
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.
Erickson HA; Jund MD; Pennell CA
Protein Eng Des Sel; 2006 Jan; 19(1):37-45. PubMed ID: 16243897
[TBL] [Abstract][Full Text] [Related]
10. [Expression, structure prediction and functional analysis of murine single-chain fragment variable antibody against human cervical cancer].
Wang Y; Li X; Chen W
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jan; 26(1):16-21. PubMed ID: 16495168
[TBL] [Abstract][Full Text] [Related]
11. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
12. Humanization of immunotoxins.
Rybak SM; Hoogenboom HR; Meade HM; Raus JC; Schwartz D; Youle RJ
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3165-9. PubMed ID: 1565609
[TBL] [Abstract][Full Text] [Related]
13. An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery.
Asai T; Wims LA; Morrison SL
J Immunol Methods; 2005 Apr; 299(1-2):63-76. PubMed ID: 15914191
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot".
Shapiro R; Ruiz-Gutierrez M; Chen CZ
J Mol Biol; 2000 Sep; 302(2):497-519. PubMed ID: 10970748
[TBL] [Abstract][Full Text] [Related]
15. Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.
Cong X; Cremer C; Nachreiner T; Barth S; Carloni P
Protein Sci; 2016 Aug; 25(8):1451-60. PubMed ID: 27110669
[TBL] [Abstract][Full Text] [Related]
16. Cloning and cytotoxicity of fusion proteins of EGF and angiogenin.
Yoon JM; Han SH; Kown OB; Kim SH; Park MH; Kim BK
Life Sci; 1999; 64(16):1435-45. PubMed ID: 10321723
[TBL] [Abstract][Full Text] [Related]
17. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
Moritz D; Groner B
Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
[TBL] [Abstract][Full Text] [Related]
18. Crystallization of single-chain Fv proteins.
Essig NZ; Wood JF; Howard AJ; Raag R; Whitlow M
J Mol Biol; 1993 Dec; 234(3):897-901. PubMed ID: 8254684
[TBL] [Abstract][Full Text] [Related]
19. Gene cloning, bacterial expression, in vitro refolding, and characterization of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg.
Yang X; Hu W; Li F; Xia H; Zhang Z
Protein Expr Purif; 2005 Jun; 41(2):341-8. PubMed ID: 15866720
[TBL] [Abstract][Full Text] [Related]
20. Bacterial single-chain antibody fragments, specific for carcinoembryonic antigen.
Ayala M; Dueñas M; Santos A; Vázquez J; Menéndez A; Silva A; Gavilondo JV
Biotechniques; 1992 Nov; 13(5):790-9. PubMed ID: 1418981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
